• Surgical Oncology Services
• Surgery Services
• Cancer Services

• American Board of Surgery, Complex General Surgical Oncology
• American Board of Surgery, Surgery

• English

• Associate Professor — Division of Surgical Oncology, Department of Surgery, UCI School of Medicine
• Associate Director — Peritoneal Malignancy Program, Department of Surgery
• Member — Alpha Omega Alpha Honor Medical Society
• Member — American College of Surgeons
• Member — Society of Surgical Oncology
• Member — American Society of Clinical Oncology
• Member — Society of Asian Academic Surgeons
• Member — American Society for Peritoneal Surface Malignancies
• Member — Society for Surgery of the Alimentary Tract

• 40 Under 40 in Cancer Award, 2021 — The Lynx Group
• Faculty Excellence in Teaching Award, 2019-2021 — Department of Surgery, University of Chicago Pritzker School of Medicine
• Junior Faculty Award, 2021 — University of Chicago Comprehensive Cancer Center
• Alpha Omega Alpha Honor Medical Society, elected 2015 — Rutgers Robert Wood Johnson Medical School

Dr. Oliver S. Eng is a board-certified UCI Health surgical oncologist who specializes in the treatment of advanced gastrointestinal cancers, including peritoneal and metastatic malignancies, sarcomas and neuroendocrine tumors.

He is an expert in treating abdominal cancers, particularly those that have spread to the peritoneum, the membrane lining the abdominal cavity. He also specializes in complex cytoreductive surgery with heated intraperitoneal chemotherapy (HIPEC). This type of high-dose chemotherapy, which is effective for many different types of cancer, is performed in the operating room after surgical removal of all visible signs of disease.

Eng earned his medical degree at Rutgers Robert Wood Johnson Medical School in New Brunswick. N.J., where he also completed a residency in general surgery. He also completed a fellowship in complex general surgical oncology at City of Hope in Duarte, Calif. He came to UCI Health and the UCI School of Medicine from the University of Chicago Medical Center, where he helped oversee one of the nation's leading peritoneal surface malignancy programs.

His research focus is on the molecular and immunologic characteristics of peritoneal tumors in order to develop innovative therapies for metastatic disease as well as to improve care and optimize outcomes for patients. He is co-author of numerous peer-reviewed manuscripts in such leading journals as Cancer Discovery, Cancer, the British Journal of Cancer and JAMA Surgery. He also has presented his work at national and international conferences and has served as a principal investigator or co-investigator on numerous clinical trials.  

In 2021, he was named one of the "40 under 40" rising stars in cancer by The Lynx Group, a medical communications company specializing in oncology and complex drugs. He also sits on the editorial boards of scientific journals and national committees in his field.

Eng sees patients at UCI Health Chao Family Comprehensive Cancer Center in Orange.

View this surgeon's faculty profile ›